Biodexa Pharmaceuticals Book Value Per Share Growth & History (BDRX)
Biodexa Pharmaceuticals's book value per share was £0.00 for fiscal 2025.
View full Biodexa Pharmaceuticals company overviewBiodexa Pharmaceuticals annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | £0.00 | -£0.00 | −95.94% |
| 2024 | 2024-12-31 | £0.00 | -£0.00 | −68.35% |
| 2023 | 2023-12-31 | £0.00 | -£0.58 | −99.33% |
| 2022 | 2022-12-31 | £0.58 | £0.58 | +37532.66% |
| 2021 | 2021-12-31 | £0.00 | £0.00 | +62.67% |
| 2020 | 2020-12-31 | £0.00 | -£1.07 | −99.91% |
| 2019 | 2019-12-31 | £1.07 | £0.79 | +285.73% |
| 2018 | 2018-12-31 | £0.28 | -£0.29 | −51.27% |
| 2017 | 2017-12-31 | £0.57 | -£0.70 | −55.21% |
| 2016 | 2016-12-31 | £1.27 | -£0.39 | −23.68% |
| 2015 | 2015-12-31 | £1.66 | — | — |
Biodexa Pharmaceuticals quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | £0.00 | -£0.00 | −95.94% |
| Q2 2025 | 2025-06-30 | £0.00 | — | — |
| Q4 2024 | 2024-12-31 | £0.00 | -£0.00 | −68.35% |
| Q4 2023 | 2023-12-31 | £0.00 | -£0.58 | −99.33% |
| Q4 2022 | 2022-12-31 | £0.58 | £0.58 | +37532.66% |
| Q4 2021 | 2021-12-31 | £0.00 | £0.00 | +62.67% |
| Q4 2020 | 2020-12-31 | £0.00 | — | — |
| Q4 2018 | 2018-12-31 | £0.28 | — | — |
Biodexa Pharmaceuticals book value per share trends
Over the last five fiscal years, Biodexa Pharmaceuticals's book value per share decreased from £0.00 to £0.00, a change of -£0.00. The latest reported quarter, Q4 2025, shows £0.00.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biodexa Pharmaceuticals source filings ↗Community posts
Biodexa advances trial enrollment as research spending and cash use rise
Biodexa ($BDRX) reported that 92 of the planned 168 participants have entered its Serenta trial, while first-half research and development spending increased to £2.92 million from £1.67 million. Spending reflected the trial and manufacturin ...